NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

ClinicalTrials.gov ID: NCT01098266

Public ClinicalTrials.gov record NCT01098266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.

Study identification

NCT ID: NCT01098266
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AGC Biologics S.p.A.; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Malignant Pleural Mesothelioma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 12, 2010 (Actual)
Primary completion: Apr 29, 2014 (Actual)
Completion: Dec 2017 (Actual)
Last update posted: Sep 17, 2019

2010 – 2017

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
Wilshire Oncology Medical Group	Corona	California	92879	—
City of Hope-Comprehensive Cancer Cente	Duarte	California	91010	—
H. Lee Moffitt ancer Center and Research Institute	Tampa	Florida	33612	—
Johns Hopkins	Baltimore	Maryland	21231	—
Columbia University	New York	New York	10032	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
UTsouthwestern medical center	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01098266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 17, 2019 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01098266 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →